Oncotelic Therapeutics, INC 10-Q quarterly reports

Oncotelic Therapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing a net loss of $1.9 million for the six months ended June 30, 2026, alongside significant non-cash gains from asset revaluations and ongoing financing activities.

Oncotelic Therapeutics reports Q1 2026 financial results, highlighting ongoing joint venture developments and new strategic partnerships in AI-enabled robotics.

Oncotelic Therapeutics reports a reduced net loss for Q3 2025, driven by the absence of goodwill impairment, while its GMP Bio joint venture advances drug pipeline and targets a 2026 Hong Kong IPO.

Oncotelic Therapeutics, Inc. reported a net income for Q2 2025 and reduced its six-month net loss, but continues to face substantial doubt about its ability to continue as a going concern due to significant accumulated losses and negative working capital.

Oncotelic Therapeutics files its Form 10-Q for the quarter ended March 31, 2025, detailing its financial results and business activities.

Oncotelic Therapeutics reported a net loss for Q3 2024, impacted by a significant goodwill impairment and ongoing operational expenses, while highlighting its joint venture progress and financial restructuring efforts.

Oncotelic Therapeutics reported its second quarter 2024 results, highlighting ongoing drug development efforts and financial challenges including a going concern warning.

Oncotelic Therapeutics reported a net loss for the first quarter of 2024, while navigating ongoing financial and operational complexities.